ArticleAllergy, asthma & immunology research2026
Immunohistochemical Study of Diamine Oxidase at the Upper Gastrointestinal Tract in Patients With Gastrointestinal-Mediated Food Allergy.
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diamine Oxidase and Gastrointestinal Diseases.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious studies have shown that diamine oxidase (DAO) is reduced in the colon of patients with gastrointestinal-mediated allergy (GMA). Therefore, we assessed the levels and physiological distribution of DAO across the normal human upper gastrointestinal tract and examined whether DAO is reduced at the upper gastrointestinal tract of patients with GMA. We also evaluated if DAO immunohistochemistry can contribute to the diagnosis of this disease.
methodsWe performed a retrospective immunohistochemical analysis on tissue samples endoscopically taken from the upper gastrointestinal tract of 21 patients with GMA and 17 food-tolerant controls. The DAO-staining intensity was analyzed semi-quantitatively: 0 = none, 1 = low intensity, 2 = medium intensity, and 3 = high intensity.
resultsOverall, DAO-staining intensity was low across the upper gastrointestinal tract both in controls (median, 1.1; 25th-75th percentile, 0.9-1.3) and in the GMA-group (1.0; 0.8-1.2). The highest DAO signal was observed at the subepithelial lamina propria of all segments. Furthermore, only the DAO-staining intensity in the duodenum was significantly lower in the GMA-group than in the controls (0.8
conclusionsThis first immunohistochemical study found DAO present at low levels and similarly distributed across the human upper gastrointestinal tract. Reduced DAO-staining intensity in GMA-patients was found only in the duodenum. This indicates that the small intestine can be most vulnerable to develop histamine-induced symptoms, and that DAO-diagnostics at the upper gastrointestinal tract should be performed only in the duodenum, when GMA is suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.